{"id":2956,"date":"2021-03-19T15:29:05","date_gmt":"2021-03-19T19:29:05","guid":{"rendered":"https:\/\/news.med.virginia.edu\/kidsmatter\/?p=2956"},"modified":"2021-04-05T09:29:01","modified_gmt":"2021-04-05T13:29:01","slug":"uva-bb-infusion-team-monoclonal-antibody-infusion-therapy","status":"publish","type":"post","link":"https:\/\/news.med.virginia.edu\/kidsmatter\/uva-bb-infusion-team-monoclonal-antibody-infusion-therapy\/","title":{"rendered":"UVA BB Infusion Team & Monoclonal Antibody Infusion Therapy"},"content":{"rendered":"

by Dr. Debbie-Ann Shirley, Division Head of Pediatric Infectious Disease<\/em><\/p>\n

UVA BB Infusion team gave their first monoclonal antibody infusion therapy to a pediatric patient March 19th! Thanks to the efforts of our BB infusion team, pharmacy services, infectious diseases, hem-onc providers and<\/p>\n

\"photo

Kendall, one of our infusion nurses (courtesy of Jenny Kuzjak)<\/em><\/p><\/div>\n

so many others, our first infusion was a success.<\/p>\n

UVA Health offers this ambulatory treatment option in the fight against COVID-19. Monoclonal Antibody Infusions (mAb) are an investigational therapy, now available under an FDA Emergency Use Authorization and may be considered for carefully selected patients who have mild to moderate symptoms and are at very high risk of disease progression or hospitalization. This therapy should not be considered the standard of care for any patient population<\/em>.<\/p>\n

Children and adolescents (age 12 – 17 y\/o, weight \u2265 40 kg) with mild to moderate COVID who meet at least 1 of the following criteria can receive this therapy,:<\/p>\n